Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023...
Braeburn receives new Complete Response Letter for Brixadi in the US PR Newswire LUND, Sweden, Dec. 15, 2021 LUND, Sweden, Dec. 15, 2021...
FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire LUND, Sweden, June 26, 2021 New PDUFA...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December...
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire LUND, Sweden, June 15, 2021 LUND, Sweden, June 15...
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid...
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden, May 3, 2021 LUND, Sweden...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지